ResMed shares have not been immune to the rise of weight loss drugs like Ozempic. But can ResMed shareholders breathe easy?
Andrew Dale
 | Andrew Dale is a partner at ECP Asset Management. He has more than 20 years' experience in financial services. Prior to joining ECP in 2014, he was managing director of Global Natural Resources with Macquarie Bank based in Hong Kong. He has also held positions with ABN Amro, Yahoo and KPMG. Andrew has a Bachelor in Accounting and Finance from the University of NSW. |
1 result for Andrew Dale:
